301015 百洋医药
已收盘 12-08 15:00:00
资讯
新帖
简况
百洋医药：锝[99mTc]肼基烟酰胺聚乙二醇双环RGD肽注射液等待专家会议
证券之星 · 12-05
百洋医药：锝[99mTc]肼基烟酰胺聚乙二醇双环RGD肽注射液等待专家会议
百洋医药（301015）披露为子公司提供担保的进展公告，12月02日股价下跌0.49%
证券之星 · 12-02
百洋医药（301015）披露为子公司提供担保的进展公告，12月02日股价下跌0.49%
百洋医药最新公告：ZapTherapeutic拟向百洋萨普增资490万美元助力ZAP-X火星舟放射外科机器人快速导入临床场景
证券之星 · 11-19
百洋医药最新公告：ZapTherapeutic拟向百洋萨普增资490万美元助力ZAP-X火星舟放射外科机器人快速导入临床场景
百洋医药：控股股东累计减持1577万股 占总股本3%
财中社 · 11-13
百洋医药：控股股东累计减持1577万股 占总股本3%
百洋医药：与北大国际医院合作放疗中心尚未启动诊疗服务
证券之星 · 11-13
百洋医药：与北大国际医院合作放疗中心尚未启动诊疗服务
百洋医药：控股股东与宣武医院共建神经科学实验室
证券之星 · 11-13
百洋医药：控股股东与宣武医院共建神经科学实验室
百洋医药(301015.SZ)与君信签署人血白蛋白产品相关经销协议
智通财经 · 11-04
百洋医药(301015.SZ)与君信签署人血白蛋白产品相关经销协议
11月4日百洋医药跌6.09%，安信医药健康股票A基金重仓该股
证券之星 · 11-04
11月4日百洋医药跌6.09%，安信医药健康股票A基金重仓该股
百洋医药控股股东持股比例降至75%
中金财经 · 11-03
百洋医药控股股东持股比例降至75%
百洋医药(301015)9月30日股东户数1.11万户，较上期减少40.83%
证券之星 · 10-30
百洋医药(301015)9月30日股东户数1.11万户，较上期减少40.83%
图解百洋医药三季报：第三季度单季净利润同比增长31.43%
证券之星 · 10-30
图解百洋医药三季报：第三季度单季净利润同比增长31.43%
百洋医药最新公告：与北大国际医院签署放射外科治疗中心合作协议
证券之星 · 10-23
百洋医药最新公告：与北大国际医院签署放射外科治疗中心合作协议
股市必读：百洋医药（301015）10月17日董秘有最新回复
证券之星 · 10-20
股市必读：百洋医药（301015）10月17日董秘有最新回复
百洋医药：ZAP-X放疗机器人治疗时间快20%
证券之星 · 10-17
百洋医药：ZAP-X放疗机器人治疗时间快20%
百洋医药（301015）披露子公司为子公司提供担保的进展公告，9月26日股价下跌0.8%
证券之星 · 09-26
百洋医药（301015）披露子公司为子公司提供担保的进展公告，9月26日股价下跌0.8%
百洋医药（301015）披露为子公司提供担保的进展公告，9月22日股价下跌2.4%
证券之星 · 09-22
百洋医药（301015）披露为子公司提供担保的进展公告，9月22日股价下跌2.4%
百洋医药取消监事会 审计委员会将代行职权
中金财经 · 09-17
百洋医药取消监事会 审计委员会将代行职权
百洋医药最新公告：与天津济坤医药科技签署战略合作协议
证券之星 · 09-12
百洋医药最新公告：与天津济坤医药科技签署战略合作协议
9月8日百洋医药涨7.11%，天弘中证医药100A基金重仓该股
证券之星 · 09-08
9月8日百洋医药涨7.11%，天弘中证医药100A基金重仓该股
北海康成-B绩后涨超12% 公司上半年实现扭亏为盈 近期与百洋医药达成战略合作
智通财经 · 09-01
北海康成-B绩后涨超12% 公司上半年实现扭亏为盈 近期与百洋医药达成战略合作
加载更多
公司概况
公司名称：
青岛百洋医药股份有限公司
所属行业：
批发业
上市日期：
2021-06-30
主营业务：
青岛百洋医药股份有限公司的主营业务是医学创新成果的产品开发、生产制造和商业化运营。公司的主要产品是药品、医疗器械、其他产品、品牌服务、其他服务。
发行价格：
7.64
{"stockData":{"symbol":"301015","market":"SZ","secType":"STK","nameCN":"百洋医药","latestPrice":22.43,"timestamp":1765177428000,"preClose":22.65,"halted":0,"volume":3105008,"delay":0,"changeRate":-0.0097,"floatShares":526000000,"shares":526000000,"eps":1.0027,"marketStatus":"已收盘","change":-0.22,"latestTime":"12-08 15:00:00","open":22.65,"high":22.75,"low":22.4,"amount":69893700,"amplitude":0.0155,"askPrice":22.43,"askSize":45,"bidPrice":22.42,"bidSize":109,"shortable":0,"etf":0,"ttmEps":1.0027,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765243800000},"marketStatusCode":5,"adr":0,"adjPreClose":22.65,"symbolType":"stock","openAndCloseTimeList":[[1765157400000,1765164600000],[1765170000000,1765177200000]],"highLimit":24.92,"lowLimit":20.38,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":525624077,"isCdr":false,"pbRate":5,"roa":"--","peRate":22.369602,"roe":"20.25%","epsLYR":1.32,"committee":-0.044643,"marketValue":11790000000,"turnoverRate":0.0059,"status":1,"floatMarketCap":11788000000},"requestUrl":"/m/hq/s/301015","defaultTab":"news","newsList":[{"id":"2589850620","title":"百洋医药：锝[99mTc]肼基烟酰胺聚乙二醇双环RGD肽注射液等待专家会议","url":"https://stock-news.laohu8.com/highlight/detail?id=2589850620","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589850620?lang=zh_cn&edition=full","pubTime":"2025-12-05 11:36","pubTimestamp":1764905774,"startTime":"0","endTime":"0","summary":"证券之星消息，百洋医药(301015)12月04日在投资者关系平台上答复投资者关心的问题。投资者提问：你好，想问下“锝[99mTc]肼基烟酰胺聚乙二醇双环RGD肽注射液”审核又暂停了，是什么原因？百洋医药回复：投资者您好，锝[99mTc]肼基烟酰胺聚乙二醇双环RGD肽注射液目前正在等待专家会议，CDE的计时处于暂停状态，属于正常审评审批流程，后续进程请关注国家药品审评中心（cde）官网，感谢您的关注与支持。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120500013405.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301015"],"gpt_icon":0},{"id":"2588513970","title":"百洋医药（301015）披露为子公司提供担保的进展公告，12月02日股价下跌0.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588513970","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588513970?lang=zh_cn&edition=full","pubTime":"2025-12-02 22:29","pubTimestamp":1764685795,"startTime":"0","endTime":"0","summary":"截至2025年12月2日收盘，百洋医药报收于22.38元，较前一交易日下跌0.49%，最新总市值为117.63亿元。公司近日发布公告称，青岛百洋医药股份有限公司为控股子公司青岛典众文化传播有限公司向兴业银行青岛分行申请的综合授信额度提供连带责任保证担保，担保最高本金限额为400万元，担保额度有效期为2025年12月1日至2026年11月30日。本次担保在公司2025年度预计对外担保额度范围内，无需另行审议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200040033.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"gpt_icon":0},{"id":"2584948858","title":"百洋医药最新公告：ZapTherapeutic拟向百洋萨普增资490万美元助力ZAP-X火星舟放射外科机器人快速导入临床场景","url":"https://stock-news.laohu8.com/highlight/detail?id=2584948858","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584948858?lang=zh_cn&edition=full","pubTime":"2025-11-19 19:01","pubTimestamp":1763550061,"startTime":"0","endTime":"0","summary":"百洋医药公告称，公司全资子公司百洋健康产业国际商贸有限公司的全资子公司河北百洋萨普医疗设备科技有限公司拟引入Zap Therapeutic增资490万美元。增资完成后，百洋萨普注册资本将增至1,000万美元，百洋健康的持股比例下降至51%。本次Zap Therapeutic向百洋萨普增资，能够充分整合双方的资金、技术、市场渠道等多方面资源优势，有利于推动ZAP-X的本土化生产，助力ZAP-X快速导入临床场景。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111900032817.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301015"],"gpt_icon":0},{"id":"2583562205","title":"百洋医药：控股股东累计减持1577万股 占总股本3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583562205","media":"财中社","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583562205?lang=zh_cn&edition=full","pubTime":"2025-11-13 19:56","pubTimestamp":1763034960,"startTime":"0","endTime":"0","summary":"11月13日，百洋医药（301015）发布公告，控股股东百洋医药集团有限公司在2025年8月12日至11月11日期间通过大宗交易和集中竞价方式累计减持1577万股，占公司总股本的3.00%。 2025年前三季度，百洋医药实现收入56.27亿元，归母净利润4.76亿元。（文章来源：财中社）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-13/doc-infxhkcu5228191.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0250","301015"],"gpt_icon":0},{"id":"2583033559","title":"百洋医药：与北大国际医院合作放疗中心尚未启动诊疗服务","url":"https://stock-news.laohu8.com/highlight/detail?id=2583033559","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583033559?lang=zh_cn&edition=full","pubTime":"2025-11-13 15:45","pubTimestamp":1763019944,"startTime":"0","endTime":"0","summary":"证券之星消息，百洋医药(301015)11月13日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，请问公司和北大国际医院合作的zap放疗中心目前是合作框架协议还是已落地开启诊疗服务了？百洋医药回复：投资者您好，2025年10月，公司与北京大学国际医院正式签署《放射外科治疗中心合作协议》，目前双方正按照协议约定全力推进合作实施落地，诊疗服务尚未正式启动，感谢您的关注与支持。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111300022870.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301015"],"gpt_icon":0},{"id":"2583755975","title":"百洋医药：控股股东与宣武医院共建神经科学实验室","url":"https://stock-news.laohu8.com/highlight/detail?id=2583755975","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583755975?lang=zh_cn&edition=full","pubTime":"2025-11-13 15:42","pubTimestamp":1763019740,"startTime":"0","endTime":"0","summary":"证券之星消息，百洋医药11月13日在投资者关系平台上答复投资者关心的问题。百洋医药回复：投资者您好， 脑神经领域公司控股股东百洋集团已于2024年与宣武医院合作共建“神经网络疾病协同创新联合实验室”，围绕神经科学领域开展前沿医学研究及科研成果转化工作。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111300022384.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301015"],"gpt_icon":0},{"id":"2580861427","title":"百洋医药(301015.SZ)与君信签署人血白蛋白产品相关经销协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2580861427","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580861427?lang=zh_cn&edition=full","pubTime":"2025-11-04 17:34","pubTimestamp":1762248871,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百洋医药(301015.SZ)公告，公司与广州市君信药业有限公司(简称“君信”)于2025年11月4日签署了《经销协议》，约定君信授予百洋医药在协议期限内在区域内特定市场独家推广、销售和经销产品安博美®的权利，并对双方权利义务等作出明确约定。据公告所示，君信股东为杰特贝林(亚太区)有限公司(简称“杰特贝林亚太”)，杰特贝林亚太通过全资子公司君信在中国进行销售运营。百洋医药自2021年3月与杰特贝林就人血白蛋白产品安博美®的零售市场开展合作，本次签署《经销协议》，将合作市场拓展至区域内特定的零售市场、广阔市场、医院市场(君信提供清单的除外)，进一步深化双方的合作。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1365092.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0250","301015"],"gpt_icon":0},{"id":"2580078864","title":"11月4日百洋医药跌6.09%，安信医药健康股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2580078864","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580078864?lang=zh_cn&edition=full","pubTime":"2025-11-04 16:33","pubTimestamp":1762245199,"startTime":"0","endTime":"0","summary":"证券之星消息，11月4日百洋医药跌6.09%，收盘报25.62元，换手率2.03%，成交量10.67万手，成交额2.73亿元。重仓百洋医药的公募基金请见下表：该股最近90天内共有2家机构给出评级，买入评级2家；过去90天内机构目标均价为30.6。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共4家，其中持有数量最多的公募基金为安信基金的安信医药健康股票A。安信医药健康股票A目前规模为4.13亿元，最新净值1.4848，较上一交易日上涨0.3%，近一年上涨52.22%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110400025556.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"gpt_icon":0},{"id":"2580216169","title":"百洋医药控股股东持股比例降至75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580216169","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580216169?lang=zh_cn&edition=full","pubTime":"2025-11-03 21:34","pubTimestamp":1762176879,"startTime":"0","endTime":"0","summary":"自2023年10月20日至2025年11月3日期间，因公司可转换公司债券“百洋转债”转股导致持股比例被动稀释，同时百洋集团通过大宗交易和集中竞价方式合计减持了12,506,890股公司股份。此次权益变动后，信息披露义务人合计持有公司股份数量由406,725,000股减少至394,218,110股，持股比例由77.46%下降至75.00%。公告指出，百洋集团目前仍有不超过公司总股本3%的减持计划尚在执行期内。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251103/31763658.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0250","301015"],"gpt_icon":0},{"id":"2579410113","title":"百洋医药(301015)9月30日股东户数1.11万户，较上期减少40.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579410113","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579410113?lang=zh_cn&edition=full","pubTime":"2025-10-30 17:48","pubTimestamp":1761817731,"startTime":"0","endTime":"0","summary":"证券之星消息，近日百洋医药披露，截至2025年9月30日公司股东户数为1.11万户，较6月30日减少7683.0户，减幅为40.83%。在医药商业行业个股中，百洋医药股东户数低于行业平均水平，截至9月30日，医药商业行业平均股东户数为4.07万户。从股价来看，2025年6月30日至2025年9月30日，百洋医药区间涨幅为39.58%，在此期间股东户数减少7683.0户，减幅为40.83%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000034540.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301015"],"gpt_icon":0},{"id":"2579874361","title":"图解百洋医药三季报：第三季度单季净利润同比增长31.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579874361","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579874361?lang=zh_cn&edition=full","pubTime":"2025-10-30 03:03","pubTimestamp":1761764600,"startTime":"0","endTime":"0","summary":"证券之星消息，百洋医药2025年三季报显示，前三季度公司主营收入56.27亿元，同比下降8.41%；归母净利润4.76亿元，同比下降25.67%；扣非净利润4.1亿元，同比下降32.87%；其中2025年第三季度，公司单季度主营收入18.76亿元，同比下降12.85%；单季度归母净利润3.13亿元，同比上升31.43%；单季度扣非净利润2.32亿元，同比下降3.01%；负债率63.59%，投资收益-615.5万元，财务费用7837.5万元，毛利率37.38%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000003030.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015"],"gpt_icon":0},{"id":"2577837159","title":"百洋医药最新公告：与北大国际医院签署放射外科治疗中心合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2577837159","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577837159?lang=zh_cn&edition=full","pubTime":"2025-10-23 17:01","pubTimestamp":1761210084,"startTime":"0","endTime":"0","summary":"百洋医药(301015.SZ)公告称，公司与北大国际医院于2025年10月23日签署《放射外科治疗中心合作协议》，双方将通过资源互补、优势协同的方式开展合作，共同建设并运营放射外科治疗中心。合作方式包括甲方负责项目运营，乙方提供ZAP-X设备和相应的技术支持。协议首次合作期限为8年，自协议签订之日起计算。该合作旨在推动高端放疗设备临床落地，提高优质医疗资源可及性，对公司业绩产生积极影响。但协议履行存在一定风险，包括外部市场环境变化、国家政策调整等。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102300025575.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301015"],"gpt_icon":0},{"id":"2576388008","title":"股市必读：百洋医药（301015）10月17日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2576388008","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576388008?lang=zh_cn&edition=full","pubTime":"2025-10-20 02:38","pubTimestamp":1760899090,"startTime":"0","endTime":"0","summary":"截至2025年10月17日收盘，百洋医药报收于25.75元，下跌3.09%，换手率0.64%，成交量3.37万手，成交额8760.52万元。董秘最新回复投资者： 请问公司代理的ZAP-X火星舟放射机器人与传统放疗设备有何区别？目前公司正在全力推动ZAP-X的临床落地和全球化制造，感谢您的关注与支持。当日关注点来自交易信息汇总：10月17日主力资金净流出1089.24万元，显示主力短期谨慎态度。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102000000988.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301015"],"gpt_icon":0},{"id":"2576089323","title":"百洋医药：ZAP-X放疗机器人治疗时间快20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2576089323","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576089323?lang=zh_cn&edition=full","pubTime":"2025-10-17 15:18","pubTimestamp":1760685491,"startTime":"0","endTime":"0","summary":"证券之星消息，百洋医药10月17日在投资者关系平台上答复投资者关心的问题。百洋医药回复：投资者您好，根据在近期召开的第67届美国放射肿瘤学会年会发布的最新研究结果表明：ZAP-X在进行脑肿瘤放疗时，对健康脑组织的保护显著优于传统通用型放疗设备；与颅脑专用放疗设备相比时，治疗效果相当，但ZAP-X的治疗时间快20%，能为脑转移瘤患者带来更高质量的治疗。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101700018392.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"gpt_icon":0},{"id":"2570987882","title":"百洋医药（301015）披露子公司为子公司提供担保的进展公告，9月26日股价下跌0.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2570987882","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570987882?lang=zh_cn&edition=full","pubTime":"2025-09-26 22:28","pubTimestamp":1758896891,"startTime":"0","endTime":"0","summary":"截至2025年9月26日收盘，百洋医药报收于27.35元，较前一交易日下跌0.8%，最新总市值为143.76亿元。该股当日开盘27.52元，最高27.7元，最低26.41元，成交额达1.26亿元，换手率为0.88%。本次担保在已审批的担保额度范围内，无需另行审议。本次担保后，百洋制药对上海制药的担保余额为7,234.00万元，上海制药可用担保额度为27,000万元。公司及控股子公司对外担保总余额为37,531.59万元，占公司最近一期经审计净资产的15.80%，无逾期担保，无对合并报表外单位担保，无诉讼担保事项。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092600039013.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301015"],"gpt_icon":0},{"id":"2569735842","title":"百洋医药（301015）披露为子公司提供担保的进展公告，9月22日股价下跌2.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2569735842","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569735842?lang=zh_cn&edition=full","pubTime":"2025-09-22 22:54","pubTimestamp":1758552858,"startTime":"0","endTime":"0","summary":"截至2025年9月22日收盘，百洋医药报收于28.46元，较前一交易日下跌2.4%，最新总市值为149.59亿元。本次担保在公司2025年度对外担保额度预计范围内，无需另行审议。担保范围包括主债权本金、利息、违约金、实现债权的费用等，保证期间为每笔债务履行期限届满之日起三年，主债权发生期间为2025年9月22日至2026年9月5日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092200035151.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301015"],"gpt_icon":0},{"id":"2568498915","title":"百洋医药取消监事会 审计委员会将代行职权","url":"https://stock-news.laohu8.com/highlight/detail?id=2568498915","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568498915?lang=zh_cn&edition=full","pubTime":"2025-09-17 19:03","pubTimestamp":1758106990,"startTime":"0","endTime":"0","summary":"中访网数据 青岛百洋医药股份有限公司(证券代码：301015)于2025年8月27日召开董事会及9月17日召开临时股东大会，审议通过了关于变更注册资本并修订《公司章程》的议案。根据新《公司法》的要求，公司决定不再设置监事会及监事职位，原监事会职权将由董事会下设的审计委员会行使。此项治理结构变更是为了完善公司法人治理，提升规范运作水平，自修订后的章程生效之日起，公司《监事会议事规则》即行废止，监事会停止履职，监事自动解任。公司表示，此次调整属于正常经营事项，符合法律规定，不会对公司日常管理、生产经营及偿债能力产生重大不利影响。债券受托管理人称将持续关注此事对可转债持有人的影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20250917/31650862.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["301015","BK0250"],"gpt_icon":0},{"id":"2566922921","title":"百洋医药最新公告：与天津济坤医药科技签署战略合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2566922921","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566922921?lang=zh_cn&edition=full","pubTime":"2025-09-12 16:55","pubTimestamp":1757667359,"startTime":"0","endTime":"0","summary":"百洋医药(301015.SZ)公告称，公司与天津济坤医药科技及其实际控制人在青岛市市北区签署了《战略合作协议》，旨在发挥双方资源优势。协议包括合作方案、甲方权利约定等内容，但具体合作内容尚需进一步协商确定。本次协议签署预计不会对公司本年度的经营业绩产生重大影响，未来随着双方业务合作的进一步加深，将有利于提升公司的持续盈利能力，对公司业绩产生积极影响。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091200025986.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK1515","09939","159938","BK1161","BK0250","301015"],"gpt_icon":0},{"id":"2565250146","title":"9月8日百洋医药涨7.11%，天弘中证医药100A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2565250146","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565250146?lang=zh_cn&edition=full","pubTime":"2025-09-08 16:33","pubTimestamp":1757320409,"startTime":"0","endTime":"0","summary":"证券之星消息，9月8日百洋医药涨7.11%创60日新高，收盘报29.09元，换手率2.93%，成交量15.42万手，成交额4.37亿元。重仓百洋医药的公募基金请见下表：根据2025基金半年报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为天弘基金的天弘中证医药100A。天弘中证医药100A目前规模为7.55亿元，最新净值0.8848，较上一交易日上涨2.38%，近一年上涨30.85%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090800020854.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000978.SH","BK0250","301015"],"gpt_icon":0},{"id":"2564862775","title":"北海康成-B绩后涨超12% 公司上半年实现扭亏为盈 近期与百洋医药达成战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2564862775","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564862775?lang=zh_cn&edition=full","pubTime":"2025-09-01 10:43","pubTimestamp":1756694580,"startTime":"0","endTime":"0","summary":"北海康成-B(01228)绩后涨超12%，截至发稿，涨9.48%，报2.54港元，成交额1031.41万港元。消息面上，北海康成发布中期业绩，上半年收益2224.8万元，同比减少50.33%；期内溢利5923.8万元，去年 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20250901/c670789894.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["BK0250","301015"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1765226700090,"stockEarnings":[{"period":"1week","weight":-0.0027},{"period":"1month","weight":-0.0751},{"period":"3month","weight":-0.2772},{"period":"6month","weight":-0.0369},{"period":"1year","weight":-0.1503},{"period":"ytd","weight":-0.0334}],"compareEarnings":[{"period":"1week","weight":0.0026},{"period":"1month","weight":-0.0184},{"period":"3month","weight":0.0307},{"period":"6month","weight":0.1534},{"period":"1year","weight":0.1528},{"period":"ytd","weight":0.1708}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"青岛百洋医药股份有限公司","boardCode":"AI0051","boardName":"批发业","stockholders":"11136人(较上一季度减少40.83%)","perCapita":"47194股","listingDate":"2021-06-30","address":"山东省青岛市市北区桐柏路88号1号楼","registeredCapital":"52562万元","survey":" 青岛百洋医药股份有限公司的主营业务是医学创新成果的产品开发、生产制造和商业化运营。公司的主要产品是药品、医疗器械、其他产品、品牌服务、其他服务。","listedPrice":7.64},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百洋医药(301015)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百洋医药(301015)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百洋医药,301015,百洋医药股票,百洋医药股票老虎,百洋医药股票老虎国际,百洋医药行情,百洋医药股票行情,百洋医药股价,百洋医药股市,百洋医药股票价格,百洋医药股票交易,百洋医药股票购买,百洋医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百洋医药(301015)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百洋医药(301015)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}